These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 9340472)
1. [Value of biguanide in therapy of diabetes mellitus]. Haupt E; Panten U Med Klin (Munich); 1997 Aug; 92(8):472-9, 505. PubMed ID: 9340472 [TBL] [Abstract][Full Text] [Related]
2. Metformin: a new treatment option for non-insulin-dependent diabetes mellitus. Goo AK; Carson DS; Bjelajac A J Fam Pract; 1996 Jun; 42(6):612-8. PubMed ID: 8656173 [TBL] [Abstract][Full Text] [Related]
3. [The risk of lacticate acidosis: a comparison of the 3 biguanides in treatment of diabetics (authors' transl)]. Irsigler K; Kritz H; Regal H; Foltin E Wien Klin Wochenschr; 1978 May; 90(10):332-7. PubMed ID: 654296 [TBL] [Abstract][Full Text] [Related]
4. Biguanides and NIDDM. Bailey CJ Diabetes Care; 1992 Jun; 15(6):755-72. PubMed ID: 1600835 [TBL] [Abstract][Full Text] [Related]
5. [Biguanides: reasons for withdrawal of drugs and remaining indications]. Bolzano K Acta Med Austriaca; 1978; 5(3):85-8. PubMed ID: 752219 [TBL] [Abstract][Full Text] [Related]
6. Biguanide-associated lactic acidosis. Case report and review of the literature. Gan SC; Barr J; Arieff AI; Pearl RG Arch Intern Med; 1992 Nov; 152(11):2333-6. PubMed ID: 1444694 [TBL] [Abstract][Full Text] [Related]
7. [Therapeutic utility of biguanides in the treatment of NIDDM]. Fujimoto S Nihon Rinsho; 1999 Mar; 57(3):657-62. PubMed ID: 10199150 [TBL] [Abstract][Full Text] [Related]
8. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Howlett HC; Bailey CJ Drug Saf; 1999 Jun; 20(6):489-503. PubMed ID: 10392666 [TBL] [Abstract][Full Text] [Related]
9. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Krentz AJ; Bailey CJ Drugs; 2005; 65(3):385-411. PubMed ID: 15669880 [TBL] [Abstract][Full Text] [Related]
10. Lactic acidosis in biguanide-treated diabetics: a review of 330 cases. Luft D; Schmülling RM; Eggstein M Diabetologia; 1978 Feb; 14(2):75-87. PubMed ID: 344119 [TBL] [Abstract][Full Text] [Related]
11. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Salpeter S; Greyber E; Pasternak G; Salpeter E Cochrane Database Syst Rev; 2002; (2):CD002967. PubMed ID: 12076461 [TBL] [Abstract][Full Text] [Related]
12. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Salpeter S; Greyber E; Pasternak G; Salpeter E Cochrane Database Syst Rev; 2003; (2):CD002967. PubMed ID: 12804446 [TBL] [Abstract][Full Text] [Related]
13. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
14. Comparative tolerability profiles of oral antidiabetic agents. Krentz AJ; Ferner RE; Bailey CJ Drug Saf; 1994 Oct; 11(4):223-41. PubMed ID: 7848543 [TBL] [Abstract][Full Text] [Related]
15. Role of metformin in treatment of diabetes mellitus. Vigneri R; Goldfine ID Diabetes Care; 1987; 10(1):118-22. PubMed ID: 3552509 [TBL] [Abstract][Full Text] [Related]
16. [Blood lactate and biguanide therapy: comparison between phenformin, metformin and buformin in 408 senile diabetics]. Bruneder H; Klein HJ Acta Med Austriaca; 1978; 5(3):88-90. PubMed ID: 752220 [TBL] [Abstract][Full Text] [Related]
17. [Traditional contraindications to the use of metformin -- more harmful than beneficial?]. Holstein A; Egberts EH Dtsch Med Wochenschr; 2006 Jan; 131(3):105-10. PubMed ID: 16418951 [TBL] [Abstract][Full Text] [Related]